Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920709 | 0.86 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL4920928 | 0.85 | ESR2 (0.35) | ESR1ESR2HSP90AA1ATMERAP1 | |
| SCHEMBL4919782 | 0.85 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL4920699 | 0.83 | KDM4E (0.33) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4915880 | 0.82 | ESR1 (0.35) | ESR1ESR2ATMERAP1KDM4E | |
| SCHEMBL4913398 | 0.82 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL4917259 | 0.80 | ESR1 (0.39) | ESR1ESR2ATMERAP1KDM4E | |
| SCHEMBL4924006 | 0.80 | ESR1 (0.36) | ESR1ESR2ATM | |
| SCHEMBL4917207 | 0.80 | ESR1 (0.38) | ESR1ESR2KDM4EALDH1A1GLA | |
| SCHEMBL4911217 | 0.79 | MCL1 (0.33) | ESR1ESR2KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2008-06-12 | — | — | US | disclosed |
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2007-03-15 | — | — | US | disclosed |
| US-7135579-B2 | Dibenzothiophene oxide compound, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-6849202-B2 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, CCNT2 | ESR1 2072/4885ESR2 2313/4885HSP90AA1 2001/4885 |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, BPNT1, PEAK1 | ESR1 4181/4885ESR2 2947/4885HSP90AA1 1559/4885 |
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, BPNT1 | ESR1 1909/4885ESR2 1398/4885HSP90AA1 2534/4885 |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, NAT1, PEAK1 | ESR1 4143/4885ESR2 2899/4885HSP90AA1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.